Related references
Note: Only part of the references are listed.Evidence and Practice Regarding the Role for CYP2D6 Inhibition in Decisions About Tamoxifen Therapy
Timothy L. Lash et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Composite Functional Genetic and Comedication CYP2D6 Activity Score in Predicting Tamoxifen Drug Exposure Among Breast Cancer Patients
Silvana Borges et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2010)
The Impact of CYP2D6 Genotyping on Tamoxifen Treatment
Roberta Ferraldeschi et al.
PHARMACEUTICALS (2010)
Time-Varying Effects of Prognostic Factors Associated With Disease-Free Survival in Breast Cancer
Loki Natarajan et al.
AMERICAN JOURNAL OF EPIDEMIOLOGY (2009)
Hazard of recurrence and adjuvant treatment effects over time in lymph node-negative breast cancer
James J. Dignam et al.
BREAST CANCER RESEARCH AND TREATMENT (2009)
Genotype-guided tamoxifen therapy: time to pause for reflection?
Timothy L. Lash et al.
LANCET ONCOLOGY (2009)
Tamoxifen, hot flashes and recurrence in breast cancer
Joanne E. Mortimer et al.
BREAST CANCER RESEARCH AND TREATMENT (2008)
Tamoxifen, soy, and lifestyle factors in Asian American women with breast cancer
Anna H. Wu et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Influence of a diet very high in vegetables, fruit, and fiber and low in fat on prognosis following treatment for breast cancer - The Women's Healthy Eating and Living (WHEL) Randomized Trial
John P. Pierce et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2007)
Effects of estrogen receptor expression and histopathology on annual hazard rates of death from breast cancer
William F. Anderson et al.
BREAST CANCER RESEARCH AND TREATMENT (2006)
Endoxifen, a secondary metabolite of tamoxifen, and 4-OH-tamoxifen induce similar changes in global gene expression patterns in MCF-7 breast cancer cells
Young Chai Lim et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2006)
Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism:: Implication for optimization of breast cancer treatment
Silvana Borges et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2006)
CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment
Y Jin et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
Pharmacological characterization of 4-hydroxy-N-desmethyl tamoxifen, a novel active metabolite of tamoxifen
MD Johnson et al.
BREAST CANCER RESEARCH AND TREATMENT (2004)
Selective serotonin-reuptake inhibitors for the treatment of hot flashes
Y De Sloover Koch et al.
ANNALS OF PHARMACOTHERAPY (2004)
Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine
V Stearns et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2003)
A randomized trial of low-dose tamoxifen on breast cancer proliferation and blood estrogenic biomarkers
A Decensi et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2003)
Estrogen receptors and distinct patterns of breast cancer relapse
KR Hess et al.
BREAST CANCER RESEARCH AND TREATMENT (2003)
A randomized trial of the effect of a plant-based dietary pattern on additional breast cancer events and survival: the Women's Healthy Eating and Living (WHEL) Study
JP Pierce et al.
CONTROLLED CLINICAL TRIALS (2002)
Venlafaxine in management of hot flashes in survivors of breast cancer: a randomised controlled trial
CL Loprinzi et al.
LANCET (2000)
Oral clonidine in postmenopausal patients with breast cancer experiencing tamoxifen-induced hot flashes: A University of Rochester cancer center community clinical oncology program study
KJ Pandya et al.
ANNALS OF INTERNAL MEDICINE (2000)
Share Paper
